Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(PWRME, IBCP, IBKC, PCH) Stock under Consideration by Stock-PR.com

<p align="center">Stock-PR Reporting</p>
<p align="center"><a title="Stock-PR website" href="stock-pr.com&quot; target="_blank"><img class="alignnone size-full wp-image-2414" title="stockpr_logo-site" alt="stockpr_logo-site" src="stock-pr.com/img/stockpr_logo-site.jpg&quot; /></a></p>
<p align="center"> </p>
<p align="center"><strong><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="pennyomega.com/?page_id=835&quot;></a></strong></p>
<p align="center"><strong><span style="COLOR: black">FREE Daily Stock Alerts From Stock-PR.com</span></strong></p>
<p style="TEXT-ALIGN: center"> </p>
<p align="center"><a title="free stock alerts, best stock alerts, hot stock alerts, stock picks, best stock picks, free stock picks" href="stock-pr.com/?page_id=1085&quot;></a></p>
<p align="center"><span style="COLOR: black"><strong><span style="COLOR: black"><strong><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><a title="stock-pr sign up" href="stock-pr.com/signup&quot; target="_blank"><img height="90" alt="chartstockalert" src="pennyomega.com/img/chartstockalert.jpg&quot; width="360" /></a></span></span></strong></span></strong></span></p>
<p align="center"> </p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong><img style="WIDTH: 176px; HEIGHT: 76px" height="63" alt="power3" hspace="0" src="pennyomega.com/img/power3.png&quot; width="152" align="bottom" border="0" /> Power3 Medical Products, Inc. (PWRME.OB)<br /></strong><br />
The NuroPro Blood Test is Power3's medical diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer's disease, ALS (Lou Gehrig's disease), and Parkinson's disease. Early detection of these diseases will allow physicians to intervene at an early stage to delay disease progression, potentially allowing patients to outlive their debilitating symptoms.<br />
<br />
The main symptoms of Parkinson's disease are usually stiffness, shaking (tremor), and slowness of movement. Other symptoms may also develop. Symptoms typically become gradually worse over time. Parkinson's disease (PD) is a chronic (persistent) disorder of part of the brain. Parkinson's disease is not usually inherited, and it can affect anyone. However, genetic (hereditary) factors may be important in the small number of people who develop the disease before the age of 50.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black"><strong>Power3 Medical Products, Inc</strong>. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 Medical applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 Medical has developed a portfolio of products including BC-SeraPro™, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a proteomic blood serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS diseases, for which it is currently engaged in Phase II clinical trials. These tests are designed to analyze an individual's proteins to detect the presence of disease, a patient's disease progression, a patient's response to a particular drug, and the mechanisms of disease present in the patient for optimal targeted therapy.</font></span></span></span></span></p>
<p><span style="COLOR: black"><span style="COLOR: black"><span style="COLOR: rgb(0,128,255)"><span style="COLOR: rgb(0,128,255)"><font color="black">Please visit Power3 Medical Products, Inc website</font> <a href="www.power3medical.com&quot;><font color="black">www.power3medical.com&lt;/font></a><font color="black">.<br />
<br />
*************************************************************************************<br />
<br />
<strong>Independent Bank Corporation (Nasdaq:IBCP)</strong> reported a first quarter 2011 net loss applicable to common stock of $8.4 million, or $1.06 per share, versus a net loss applicable to common stock of $14.9 million, or $6.21 per share, in the prior-year period. The reduced loss was primarily due to declines in the provision for loan losses and in non-interest expenses that were partially offset by a decline in net interest income.<br />
<br />
 Independent Bank Corporation operates as a holding company for the Independent Bank that provides various commercial banking services in Michigan. The company offers various deposit products, including non-interest bearing demand deposits, time deposits, checking and savings accounts, and NOW accounts.<br />
<br />
***************************************<br />
<br />
<strong>IberiaBank Corp. (Nasdaq:IBKC)</strong> reported operating results for the first quarter ended March 31, 2011. For the quarter, the Company reported income available to common shareholders of $15 million and fully diluted earnings per share ("EPS") of $0.54. Excluding one-time acquisition and conversion costs, earnings were $16 million. On that basis, EPS was $0.58, an increase of 10% compared to the fourth quarter of 2010 ("linked quarter basis").ax-equivalent net interest margin expanded 45 basis points, from 3.10% to 3.55%, and net interest income expanded $6 million, or 9%, on a linked quarter basis. Loan growth during the first quarter of 2011 of $149 million, or 3%, excluding FDIC-related loans. Core deposit growth (excluding time deposits) of $184 million, or 4% during the first quarter of 2011. Continued asset quality strength; nonperforming assets ("NPAs") to total assets ratio of 1.01% at March 31, 2011. Capital ratios remain strong; Tier 1 leverage ratio of 11.65%, up 41 basis points compared to year-end 2010.<br />
<br />
IBERIABANK Corporation operates as the holding company for IBERIABANK that offers commercial and retail banking products and services in the United States.<br />
<br />
***************************************<br />
<br />
<strong>Potlatch Corporation (Nasdaq:PCH)</strong> reported financial results for the first quarter ended March 31, 2011. Total consolidated revenues increased 16 percent from $105.4 million in Q1 2010 to $122.2 million in Q1 2011. Net earnings for the quarter were $7.7 million, or $0.19 per diluted common share, compared to $1.2 million, or $0.03 per diluted common share for Q1 2010. Q1 2010 earnings included a $3.0 million after-tax charge, or $0.07 per share, related to health care reform legislation passed in Q1 2010. Cash provided by operating activities from continuing operations was $20.2 million for Q1 2011 compared to $11.9 million for Q1 2010.<br />
<br />
Potlatch Corporation operates as a real estate investment trust (REIT) that owns and manages timberlands located in Arkansas, Idaho, Minnesota and Wisconsin in the United States.<br /></font></span></span></span></span></p>
<p align="center"> </p>
<p align="center"> </p>
<p align="center">**************************************************************</p>
<p align="center"><strong>THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!</strong></p>
<p><strong><font color="blue"><font color="red">Disclaimer:</font> Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (<font color="red">Read more at <a href="stock-pr.com/?page_id=40&quot; target="_blank"><font color="red">stock-pr.com/disclaimer&lt;/font></a></font>).</font></strong><span style="COLOR: red"><span style="COLOR: red"><strong><font color="blue">Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.</font><font color="red">Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRME.OB).<br />
<br /></font></strong></span></span></p>
<p align="center">Sign Up For Free Stock Alerts At <a href="stock-pr.com/signup&quot; target="_blank">stock-pr.com/signup&lt;/a></p>
<p align="center"><a href="www.crownequityholdings.com&quot; target="_blank"><img alt="stock-pr.com/img/stock-pr_buscard.jpg&quot; src="stock-pr.com/img/stock-pr_buscard.jpg&quot; /></a></p>